Psoriasis: preventing quality of life impairment
On 22 July Massimo Zaninelli, CEO of Maxer Consulting, presented the training session dedicated to “Clinical studies: from submission to AIC” to the young participants of Missione MSL. The lecture outlined the overview of the process that leads from the design of a study to the marketing authorization of the… read more →
By adopting a data-driven, objective method based on public data, Maxer can profile doctors’ behaviours on the web and social media and classify their familiarity with digital media. Based on the results obtained, it is possible to identify each doctor’s favourite channels and media for digital medical-scientific information activity, which… read more →
We are pleased to announce that EryDel S.p.A., now part of Quince Therapeutics Inc., has appointed Maxer Consulting to deliver its Clinical Trial Disclosure and Data Transparency program for 2023-24. Maxer will carry out the activities necessary to ensure Erydel’s compliance with both the regulations in force in the European… read more →
On October 13, Massimo Zaninelli held the lecture Introduction to EMA Clinical Trial Information System (CTIS) at the two-year Master on Regulatory Discipline “G. Benzi” – University of Pavia. CTIS serves to implement EU pharmaceutical law in the Clinical Trials Regulation (Regulation (EU) No 536/2014) and supports the flow of information between clinical trial… read more →
Maxer, in collaboration with Aristea, coordinated the Rising project, a cycle of Board Meetings promoted by AbbVie and dedicated to two main themes: the effects of psoriasis at the level of social stigma, comorbidity, coping strategies and external factors, better known as Cumulative Life Course Impairment (CLCI) the evolution of… read more →
As part of the 2023 consultancy activities on Clinical Trial Disclosure and Data Transparency, Zambon S.p.A. asked Maxer to provide the course entitled “ClinicalTrials.gov and CT.gov PRS Modernization”. The course, held on 23 April, touched on the following topics: Modernization of ClinicalTrials.gov Beta version update process Beta versions of ClinicalTrials.gov… read more →
We are pleased to announce that last March Italfarmaco S.p.A. appointed Maxer Consulting to carry out its Clinical Trial Disclosure (CTD) and Data Transparency activities for 2023. The agreement provides for Maxer to ensure Italfarmaco’s compliance with the results of the clinical studies entrusted to Maxer by publishing them on… read more →
Maxer is pleased to relaunch the article published by AboutPharma in the December 2022/January 2023 issue, entitled A data-driven method: following “traces” on the web helps to profile doctors. The article, written by Massimo Zaninelli, Laura Gatti, Marco Santagostino and Fausto Volonté, presents the method of profiling health professionals’ digital… read more →
Maxer has implemented a programme to help commercial and non-commercial clinical trial sponsors get accustomed to the EMA Clinical Trial Information System (CTIS).and The programme also supports the update of the sponsor’ organisation models to the CTIS requirements. The programme includes two training sessions– the first is dedicated to… read more →
